Friday 6 November 2026 Export AIM’s income statement to Excel — free account

AIM ImmunoTech Inc.

AIM Healthcare Biotechnology

AIM ImmunoTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88,000.00, down 48.2% from fiscal 2024.

Revenue: +4.00%
EPS: +88.3%
Free cash flow: −167.5%

Quarter to June 2026, against a year earlier

Insider buying

0.16 0.01 +6.67%

Follow AIM

Alert me

Market cap: $6.1M
P/E: 0.0×
Fwd P/E: −0.2×
Dividend yield: —
F-score: 3/9
Altman Z: −113.91
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.02

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	4	2	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 6.07

Revenue ttm 0.10

Net income ttm (14.27)

Free cash flow ttm (14.62)

Net debt Q (9.96)

Valuation

P/E 0.00

Forward P/E (0.16)

Price / sales 28.83

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.35

Financial health

Current ratio Q 2.11

Debt / equity Q 0.00

Interest coverage Q (11.91)

Growth

Revenue growth Q +4.00%

Operating income growth Q −32.77%

EPS, this year +90.02%

EPS, next year A +37.21%

Revenue, next year A −15.91%

EPS, past 5 yrs —

EPS, next 5 yrs A +58.64%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 22.85%

10-year low 10-year high

P/B against its own 10 years 4.92%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	13	4	3	10
Receivables	1	—	0	—
Inventory	—	—	—	—
Other	—	—	—	—
	15	4	3	10

	2023	2024	2025	Q'26
Payables	6	6	2	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	9	10	6	5

Compound Annual Growth %

	10y	5y	3y
Sales	(4.05%)	(11.60%)	(14.54%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.12 Actual −0.43

−1.23 −0.91 −0.59 −0.26 0.06

Q3 FY25 Beat +0.66

Q4 FY25 Beat +0.50

Q1 FY26 Beat +0.39

Q2 FY26 Miss −0.31

Q3 FY26 — Nov 16

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.98	−0.32	Beat by 0.66
Q4 FY25	−0.94	−0.44	Beat by 0.50
Q1 FY26	−1.08	−0.69	Beat by 0.39
Q2 FY26	−0.12	−0.43	Miss by 0.31
Q3 FY26	−0.09	—	Reports 16 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.69)	(0.43)	—	—	—
’25	(5.00)	(3.68)	(1.57)	(1.43)	(8.62)
’24	(12.00)	(3.00)	(6.00)	(10.00)	(31.00)
’23	(8.00)	(10.00)	(16.00)	(26.00)	(60.00)
’22	(8.00)	(10.00)	(13.00)	(9.00)	(40.00)
’21	(8.00)	(12.00)	(8.00)	(12.00)	(40.00)
’20	(22.00)	(11.00)	(8.00)	(9.00)	(45.00)

Fiscal quarters ending in the months shown.

Revenue $m

	Sep	Dec	Year
’26	—	—	—
’25	0	0	0
’24	0	0	0
’23	0	0	0
’22	0	0	0
’21	0	0	0
’20	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(5)	—	—	—
’25	(2)	(2)	(5)	(2)	(11)
’24	(5)	(3)	(3)	(4)	(15)
’23	(4)	(2)	(6)	(10)	(21)
’22	(3)	(2)	(5)	(6)	(16)
’21	(3)	(2)	(3)	(6)	(14)
’20	(3)	(1)	(3)	(3)	(10)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(5)	—	—	—
’25	(2)	(2)	(5)	(2)	(11)
’24	(5)	(3)	(3)	(4)	(15)
’23	(4)	(2)	(6)	(10)	(22)
’22	(3)	(2)	(5)	(3)	(12)
’21	(3)	(1)	(4)	(6)	(14)
’20	(3)	(1)	(3)	(3)	(11)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	0	0	0	0	0	0	0	0	0	0	0		(0.5%)	0	0	0	(5.6%)
	Gross margin, %	(1,104.35)	(170.71)	(140.87)	(537.86)	(394.48)	(529.63)	100.00	79.21	81.76	(45.45)	(23.16)		+1,058.9 pt	Powerpack AIM ImmunoTech Inc.’s next three years, line by line Analysts expect revenue to shrink 5.6% a year to 2028 — slower than the −0.5% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(8)	(8)	(10)	(9)	(14)	(19)	(19)	(29)	(17)	(14)	(14)		+7.1%
	EBT margin, %	(8,154.35)	(1,889.93)	(2,677.66)	(6,717.14)	(8,834.36)	(14,168.15)	(13,790.78)	(14,337.62)	(10,188.24)	(15,861.36)	(15,021.05)		(7,707.0) pt
	Net income	(8)	(8)	(10)	(9)	(14)	(19)	(19)	(29)	(17)	(14)	(14)		+7.1%
Per share, $
Per share, $	Revenue	18.40	67.23	36.70	3.85	0.51	0.29	0.29	0.42	0.30	0.05	0.01		(47.6%)
	Earnings	(1,497.80)	(1,277.53)	(969.16)	(258.00)	(45.00)	(40.00)	(40.00)	(60.00)	(31.00)	(8.62)	(4.12)		(43.6%)
	Cash flow	(1,476.00)	(1,221.69)	(1,064.00)	(249.09)	(32.56)	(29.50)	(33.52)	(43.77)	(26.58)	(6.77)	(0.84)		(45.0%)
	Capex	(90.80)	(10.62)	92.30	(10.03)	(1.87)	(0.82)	7.55	(1.11)	(0.99)	(0.23)	(0.01)		(48.4%)
	Free cash flow	(1,566.80)	(1,232.31)	(971.70)	(259.12)	(34.43)	(30.32)	(25.97)	(44.88)	(27.57)	(7.00)	(0.85)		(45.2%)
	Book value	3,099.60	1,338.92	517.40	369.29	192.51	120.15	80.06	21.06	(2.36)	(6.04)	0.45		n/m
	Shares, m	0	0	0	0	0	0	0	0	1	2	7		+90.1%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	164.84	22.55	21.68	5.21	349.30	322.30	110.31	114.14	65.18	37.48	28.83		121.3
	P/B	0.98	1.13	1.54	0.16	0.94	0.77	0.41	2.42	0.00	0.00	0.35		0.8
	EV/Sales	101.09	21.93	23.56	(1.50)	122.95	(32.68)	(125.84)	53.28	43.98	16.04	(71.38)		22.3
	EV/FCF	(1.18)	(1.20)	(0.89)	0.06	(1.83)	0.31	1.42	(0.49)	(0.48)	(0.12)	0.46		(0.4)
Cash, $m
Cash, $m	Operating cash flow	(7)	(8)	(11)	(9)	(10)	(14)	(16)	(21)	(15)	(11)	(14)		+4.5%
	Capex	0	0	1	0	(1)	0	4	(1)	(1)	0	0		(2.0%)
	Free cash flow	(8)	(8)	(10)	(9)	(11)	(14)	(12)	(22)	(15)	(11)	(15)		+4.2%
Balance, $m
Balance, $m	Working capital	5	1	(1)	9	39	50	35	6	(5)	(3)	5		n/m
	Net debt	(6)	0	1	(3)	(37)	(48)	(34)	(13)	(4)	(2)	(10)		(10.7%)
	Shareholders’ equity	15	9	5	13	61	57	38	10	(1)	(10)	8		n/m
Returns, %
Returns, %	ROA	(36.00)	(49.93)	(70.06)	(54.36)	(33.75)	(31.28)	(39.61)	(96.75)	(123.76)	(194.00)	(169.28)		(158.0) pt
	ROIC	(89.59)	(84.63)	(122.49)	(71.40)	(38.81)	(134.97)	(252.22)	0.00	0.00	0.00	0.00		+89.6 pt
	ROE	(41.83)	(68.25)	(141.63)	(105.44)	(39.33)	(32.77)	(41.40)	(122.42)	(421.26)	251.38	(2,382.30)		+293.2 pt
People
People	Employees	34	27	33	26	23	21	22	28	23	21	—		(5.2%)
	Revenue/emp, $m	0.00	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00	—		+5.0%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
FBLG FibroBiologics Inc.	$6.4M	— (loss-making)	—	—	n/m	+21.59% (above 0%: growing)	—	0.00%	Compare
ENVB Enveric Biosciences, Inc.	$6.3M	— (loss-making)	— (loss-making)	−7.28% (below 0%: shrinking)	n/m	−29.34% (below 0%: shrinking)	0.00%	0.00%	Compare
APRE Aprea Therapeutics, Inc.	$6.2M	— (loss-making)	— (loss-making)	−98.40% (below 0%: shrinking)	n/m	−5.22% (below 0%: shrinking)	100.00%	0.00%	Compare
AIM AIM ImmunoTech Inc.	$6.1M	— (loss-making)	— (loss-making)	+4.00% (above 0%: growing)	n/m	−167.46% (below 0%: shrinking)	80.77%	(13,511.54%)
EVGN Evogene Ltd.	$6.0M	— (loss-making)	— (loss-making)	−35.02% (below 0%: shrinking)	n/m	+17.72% (above 0%: growing)	40.63%	(738.62%)	Compare
CNSP CNS Pharmaceuticals, Inc.	$5.9M	— (loss-making)	—	—	n/m	+33.70% (above 0%: growing)	0.00%	0.00%	Compare
XCUR Exicure, Inc.	$5.8M	— (loss-making)	— (loss-making)	−80.51% (below 0%: shrinking)	n/m	+65.38% (above 0%: growing)	100.00%	0.00%	Compare
ORGS Orgenesis Inc.	$5.7M	— (loss-making)	1.0×	+82.42% (above 0%: growing)	n/m	−317.93% (below 0%: shrinking)	2,780.73%	(6,044.52%)	Compare
CRIS Curis, Inc.	$5.7M	— (loss-making)	— (loss-making)	−65.98% (below 0%: shrinking)	n/m	−20.44% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$5.9M	—	—	−50.50%	—	+6.25%	100.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 September 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	640.24k	640.24k	3.64
2024	1.09m	1.07m	63.87
2023	1.43m	1.46m	141.94

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

AIM ImmunoTech Inc. (AIM) Latest News

7 Oct

Impact 4 · 9:14 AM · GlobeNewswire

AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays

5 Oct

Impact 3 · 9:22 AM · GlobeNewswire

AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential

1 Oct

Impact 4 · 9:02 AM · GlobeNewswire

AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data

30 Sep

Impact 3 · 8:44 AM · GlobeNewswire

AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video

22 Sep

Impact 4 · 8:55 AM

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

9 Sep

Impact 3 · 9:03 AM

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video

2 Sep

Impact 4 · 8:43 AM

AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041

31 Aug

Impact 4 · 8:51 AM

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039

11 Aug

Impact 3 · 5:04 PM · MarketBeat transcript

Aimia Q2 Earnings Call Highlights

Impact 3 · 6:00 AM

AIMIA REPORTS SECOND QUARTER 2026 RESULTS

3 Aug

Impact 4 · 8:33 AM

AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point

7 Jul

Impact 3 · 9:03 AM

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

24 Jun

Impact 4 · 8:29 AM · GlobeNewswire

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

18 Jun

Impact 3 · 9:01 AM

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

9 Jun

Impact 3 · 9:29 AM · GlobeNewswire

AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules

8 Jun

Impact 4 · 8:33 AM · GlobeNewswire

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

1 Jun

Impact 4 · 10:19 AM · Stocktwits

AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead

Impact 4 · 8:58 AM · GlobeNewswire

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

27 May

Impact 4 · 8:47 AM · GlobeNewswire

AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

20 May

Impact 3 · 3:02 PM · GlobeNewswire

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

19 May

Impact 3 · 8:02 AM · GlobeNewswire

AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities

14 May

Impact 4 · 8:41 AM · GlobeNewswire

AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer

13 May

Impact 3 · 9:47 AM · Benzinga transcript

Transcript: Aimia Q1 2026 Earnings Conference Call

7 May

Impact 4 · 8:23 AM · GlobeNewswire

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

16 Apr

Impact 4 · 9:00 AM · GlobeNewswire

AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP

1 Apr

Impact 3 · 9:04 AM · CNW Group

AIMIA PROVIDES UPDATE ON ITS SHARE BUYBACKS

24 Mar

Impact 4 · 10:43 AM · Insider Monkey

Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial

Impact 4 · 6:00 AM · CNW Group

AIMIA REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS

Impact 3 · 11:36 AM · MarketBeat

Aimia Q4 Earnings Call Highlights

18 Mar

Impact 4 · 8:36 AM · GlobeNewswire

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

AIM ImmunoTech Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 30 September 2026

Chief executive’s pay

AIM ImmunoTech Inc. (AIM) Latest News

7 Oct

5 Oct

1 Oct

30 Sep

22 Sep

9 Sep

2 Sep

31 Aug

11 Aug

3 Aug

7 Jul

24 Jun

18 Jun

9 Jun

8 Jun

1 Jun

27 May

20 May

19 May

14 May

13 May

7 May

16 Apr

1 Apr

24 Mar

18 Mar

Stockrow Weekly